NCT00634894View on ClinicalTrials.gov

Femara (Letrozole) Versus Placebo for Patients With Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

March 31, 2008

Primary Completion Date

September 30, 2008

Study Completion Date

September 30, 2008

Conditions
Ovarian CancerFallopian Tube CancerPeritoneal Cancer
Interventions
DRUG

Femara

2.5 mg by mouth daily x 12 weeks

DRUG

Placebo

Placebo capsule by mouth daily x 12 weeks

Trial Locations (1)

77030

UT MD Anderson Cancer Center, Houston

Sponsors

Collaborators (1)

Novartis Pharmaceuticals
All Listed Sponsors
collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

M.D. Anderson Cancer Center

OTHER